Skip to main content

Table 3 Comparison of the clinical factors between patients with and without AE-ILD

From: Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer

  AE-ILD (−) (n = 41) AE-ILD (+) (n = 7) p value
Age (years) 69.0 (66.0–75.0) 65.0 (63.0–66.5) 0.019
Sex (male, %) 34 (82.9) 6 (85.7) 1.00
Smoking status    0.57
 Current or former 35 (85.4) 7 (100)  
 Never 6 (14.6) 0 (0)  
 Previous steroid therapy 4 (9.8) 2 (28.6) 0.21
ECOG PS    0.59
 0–1 33 (80.5) 7 (100)  
 ≥2 8 (19.5) 0 (0)  
Stage    1.00
 III 8 (19.5) 1 (14.3)  
 IV 33 (80.5) 6 (85.7)  
Classification of ILD    1.00
 IIPs 38 (92.7) 7 (100)  
 Non-IIPs 3 (7.3) 0 (0)  
ILD pattern    0.42
 UIP pattern 22 (53.7) 2 (28.6)  
 Non-UIP pattern 19 (46.3) 5 (71.4)  
SpO2 at rest (%) 96.0 (95.0–9.07) 96.0 (95.0–97.0) 0.82
FVC (% predicted) 89.0 (78.5–100) 82.0 (81.0–101.0) 0.74
LDH (U/L) 219.0 (194.0–253.0) 224.0 (202.5–257.5) 0.74
KL-6 (U/ml) 789.0 (530.2–1196.0) 893.0 (537.0–1048.0) 0.86
CRP (mg/dl) 0.9 (0.3–1.5) 0.9 (0.8–2.8) 0.58
First-line regimens    0.86
 CDDP + PEM 10 (24.4) 1 (14.3)  
 CBDC + PEM 21 (51.2) 4 (57.1)  
 PEM 3 (7.3) 1 (14.3)  
 CBDCA + PTX 7 (17.1) 1 (14.3)  
 Bev-containing regimens 17 (41.5) 0 (0) 0.041
 PEM-containing regimens 34 (82.9) 6 (85.7) 1.00
  1. Data are expressed as group median (interquartile range) or number of patients (%). The p values refer to comparisons between patients with and without AE-ILD. ECOG PS Eastern Cooperative Oncology Group performance status, ILD interstitial lung disease, IIPs idiopathic interstitial pneumonias, UIP usual interstitial pneumonia, FVC forced vital capacity, SpO2 percutaneous oxygen saturation, LDH lactate dehydrogenase, KL-6 Krebs von den Lungen-6, CRP C-reactive protein, CDDP cisplatin, PEM pemetrexed, CBDCA carboplatin, PTX paclitaxel